<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230504058083N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-15</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the Effect of Erector Spinae Plane Block during Posterior Cervical Spine Fusion Surgery with Lateral Mass Fixation on Postoperative Axial Pain</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the Effect of Erector Spinae Plane Block during Posterior Cervical Spine Fusion Surgery with Lateral Mass Fixation on Postoperative Axial Pain</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71679</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using the block randomization approach, the intervention and control groups will be assigned, and the randomization sequence will be performed based on the website https://www.sealedenvelope.com/simple-randomiser/v1/lists. For this purpose, 60 coded packets will be prepared, 30 of which will contain the intervention of anesthesia and the other 30 will not. The treating physician and researcher will remain unaware of the content of the packet until the last moment, and the patient's packet will be opened during the operation, and the patient will be placed in one of the two groups based on that, Blinding description: Sixty coded packets will be prepared, 30 of which will contain the intervention of anesthesia and the other 30 will not. The treating physician and researcher will remain unaware of the content of the packet until the last moment, and the patient's packet will be opened during the operation, and the patient will be placed in one of the two groups based on that. Additionally, the patient will remain unaware of which group they belong to until the end of the study. Finally, the two groups will be delivered to the statistical analyzer for analysis without the analyzer being informed of the group type for each code.</study_design>
      <phase>2-3</phase>
      <hc_freetext>تنگی کانال گردن.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: A group of 30 people receive 4 milligrams of dexamethasone and 15 cc of 0.5% bupivacaine (maximum injectable dose of bupivacaine for local injection is 175 milligrams) injected into each erector spinae plane muscle site at the end of the surgical procedure and throughout the surgical site where the skin incision is made, after washing and before closing the fascia. This injection is performed by the neurosurgeon performing the surgical procedure. Intervention 2: Control group: A group of 30 people who will not receive this drug injection, instead, they will receive 16 cc of placebo (normal saline).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The results and data of this study will be published honestly, accurately, and completely. Both negative and positive results, as well as budget sources, organizational affiliations, and conflicts of interest, if any, will be fully disclosed.

When:
The start of the data and results access period for the study will be one month after the publication of the results.

To whom:
The data will only be accessible to researchers employed at academic and scientific institutions and individuals who participated in this study.

Conditions:
The use of the data from this study is only authorized for the purpose of improving patients' health.

Where to obtain:
To access the data, you can contact the researcher of this project via email and submit a request to access the data. The email address is dmr.rostami@gmail.com, and the name of the researcher is Mohammad Rostami Ravari.

How to obtain:
The requester must clearly state their purpose for accessing the data with sufficient documentation, and if it complies with ethical and scientific principles and helps improve patient health, the data from this study will be provided to them.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Rostami Ravari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shariati Hospital, Educational, Research and Treatment Center, North Kargar Street, Jalal Al Ahmad Intersection</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 8490 1000</telephone>
        <email>dmr.rostami@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Rostami Ravari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shariati Hospital, Educational, Research and Treatment Center, North Kargar Street, Jalal Al Ahmad Intersection</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 8490 1000</telephone>
        <email>dmr.rostami@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>no preoperative lower limb palsy
no lower limb paralysis that would impede the patient's ability to walk
no addiction to drugs (except for smoking) that would interfere with pain assessment
non-pregnancy
absence of a severe concurrent illness that would interfere with the investigation of the cause of pain
no obstructive cardiac disease
no acute neck trauma
patient's full consent to participate in the study
age between 18 and 65 years
fusion in the C3-C7 range
no sickle cell disease in the patient
no sensitivity to epinephrine and anesthetics
no underlying cancer</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>pregnancy
a significant drop in lower limb force after the surgery that would impede the patient's ability to walk after the operation
acute neck trauma
any accompanying illness that would interfere with the investigation of the cause of pain
any concurrent surgery outside the C3-C7 range
infection at the surgical site up to one week after the operation
age below 18 years and above 65 years
a severe diagnosed psychiatric illness or a psychiatric illness that the patient is taking medication for or has a history of taking medication to treat
if the patient has a gain
If the patient undergoes simultaneous neck surgery through the anterior approach
addiction to drugs (except for smoking)
if the reason for the surgery is a tumor</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M99.41</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Connective tissue stenosis of neural canal of cervical region</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: A group of 30 people receive 4 milligrams of dexamethasone and 15 cc of 0.5% bupivacaine (maximum injectable dose of bupivacaine for local injection is 175 milligrams) injected into each erector spinae plane muscle site at the end of the surgical procedure and throughout the surgical site where the skin incision is made, after washing and before closing the fascia. This injection is performed by the neurosurgeon performing the surgical procedure</i_keyword>
      <i_keyword>Control group: A group of 30 people who will not receive this drug injection, instead, they will receive 16 cc of placebo (normal saline).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Postoperative pain intensity. Timepoint: 6 hours, 24 hours, 48 hours, and 1 week after surgery. Method of measurement: Numeric Rating Scale score.</prim_outcome>
      <prim_outcome>Amount of narcotic analgesic consumption. Timepoint: 24 hours and 48 hours after surgery. Method of measurement: The dose of injected narcotic medication is recorded in milligrams in the documents included in the file during 24 and 48 hours after the end of the surgery.</prim_outcome>
      <prim_outcome>Type of analgesic used. Timepoint: 24 hours and 48 hours after surgery. Method of measurement: Investigating the type of medication injected based on the documents included in the file during 24 and 48 hours after the end of the surgery.</prim_outcome>
      <prim_outcome>The first time the patient walks after surgery. Timepoint: Up to 48 hours after surgery. Method of measurement: The duration from the end of surgery until the patient starts walking in the ward, as observed directly and asked from the patient.</prim_outcome>
      <prim_outcome>The first time the patient requests pain medication. Timepoint: Up to 48 hours after surgery. Method of measurement: The time from the end of surgery until the patient requests pain medication for pain relief, recorded in hours with the help of patient questioning.</prim_outcome>
      <prim_outcome>Number of cervical fusion levels. Timepoint: At the end of the surgical procedure. Method of measurement: The number of cervical vertebrae that have screws inserted into them is recorded through direct observation of radiology images taken after the surgery.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-29</approval_date>
        <contact_name>Research Ethics Committees of Shariati Hospital</contact_name>
        <contact_address>University of Tehran Married Students Dormitory, Daneshju Blvd, Tehran-Karaj Highway, Tehran, Iran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
